vaccine allows the use of the FDA approved surrogate markers of potency and efficacy. These surrogate markers enable rapid development of manufacturing capacity and rapid clinical trial demonstration of efficacy. This new method of influenza vaccine antigen production coupled with the high-volume automated production of a room temperature stable single-dose vaccination kit may enable a rapid response platform capable of addressing pandemic biological threats.